| Item type |
文献 / Documents(1) |
| 公開日 |
2018-05-21 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.2152/jmi.62.195 |
|
|
言語 |
ja |
|
|
関連名称 |
10.2152/jmi.62.195 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
The malignant progression effects of regorafenib in human colon cancer cells |
|
言語 |
en |
| 著者 |
トミダ, チサト
アイバラ, カナ
ヤマギシ, ナオコ
ヤノ, チアキ
ナガノ, ヒカル
安倍, 知紀
オオノ, アヤコ
平坂, 勝也
二川, 健
(手嶋)近藤, 茂忠
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
A number of anti-angiogenic drugs targeting vascular endothelial growth factor receptors (VEGF-R) have developed and enabled significant advances in cancer therapy including colorectal cancer. However, acquired resistance to the drugs occurs, leading to disease progression, such as invasion and metastasis. How tumors become the resistance and promote their malignancy remains fully uncertain. One of possible mechanisms for the resistance and the progression may be the direct effect of VEGF-R inhibitors on tumor cells expressing VEGF-R. We investigated here the direct effect of a VEGF-R-targeting agent, regorafenib, which is the first small molecule inhibitor of VEGF-Rs for the treatment of patients with colorectal cancer, on phenotype changes in colon cancer HCT116 cells. Treatment of cells with regorafenib for only 2 days activated cell migration and invasion, while vehicle-treated control cells showed less activity. Intriguingly, chronic exposure to regorafenib for 90 days dramatically increased migration and invasion activities and induced a resistance to hypoxia-induced apoptosis. These results suggest that loss of VEGF signaling in cancer cells may induce the acquired resistance to VEGF/VEGF-R targeting therapy by gaining two major malignant phenotypes, apoptosis resistance and activation of migration/invasion. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
angiogenesis inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
VEGF receptor tyrosine kinase inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
regorafenib |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
colon cancer cells |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
malignant phenotype |
| 書誌情報 |
en : The Journal of Medical Investigation
巻 62,
号 3-4,
p. 195-198,
発行日 2015-08
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13496867 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13431420 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11166929 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12022913 |
| 出版者 |
|
|
出版者 |
Faculty of Medicine Tokushima University |
|
言語 |
en |
| EID |
|
|
識別子 |
317681 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
jmi_62_3-4_195.pdf (361 KB)
